

Key patient insights in one place

Women diagnosed during the earliest stages of breast cancer have better outcomes and survival rates.¹ Volpara® Scorecard™ software provides your breast care team with the insights they need to find cancer earlier.

Easily accessed from the radiologist's workstation, Volpara Scorecard streamlines your workflow to improve clinical decision-making and create a better patient experience.

1 shared view, many end users

ONE

Volpara® TruDensity™

Automated, objective, volumetric breast density (VBD) measurements and a breast density category for an objective and consistent assessment²

TWO

Volpara® TruRadDose™

Personalised radiation organ dose, consistent across manufacturers for study dose quality control

THREE


Volpara® TruPressure™

Compression pressure insights for optimal image quality and patient comfort

FOUR

Clear risk assessment input

For all clinicians involved in breast care, display of average VBD%—the only validated, automated breast density measurement for the Tyrer-Cuzick 8 risk model³



Automatic
density assessment



Enable risk
assessment



Engage referrers



Smart screening

Clinical decision support for personalized breast care

Volpara Scorecard is available to radiologists during mammography interpretation as a DICOM® Secondary Capture Image. This customisable image also includes these features:

- Volpara TruRadDose and Volpara TruPressure clinical functions, which provide quality control measures for study dose and compression pressure, respectively.
- Integration with AI software that informs the likelihood of the presence of cancerous lesions. Insights can be displayed on the Scorecard or included in DICOM Mammography CAD Structured Reports.
- Alerts that indicate when the patient meets high-risk thresholds.

Evidence for essential screening

Referring physicians and insurers require evidence of high breast density. Volpara Scorecard's objective, science-based measures help you triage women at high risk to the screening or diagnostic testing essential for better outcomes.

Effective triage for time and cost savings

Personalised screening scores help the radiologist guide a woman with high breast density to essential imaging while she's still in the facility for her annual mammogram, saving her an extra trip and the cost of scheduling an additional appointment.

Combined with Volpara® Analytics™ software, Volpara Scorecard assists in identifying patient populations with high breast density that may require additional services.

Find out more

About Volpara Scorecard

To see how the new Volpara Scorecard can support your breast screening program, contact your Lunit representative for a live demonstration, or visit our website.

Why radiologists choose Volpara's automated breast density assessment:

4-6x

Greater risk for clients with dense breasts to develop breast cancer when compared to those with fatty breasts

-30%

Sensitivity in mammographic cancer detection for women with dense breasts when compared to those with fatty breasts

89%

Average agreement with the VDG category*

96%

Average agreement with Volpara's assessment of fatty (a/b) or dense (c/d)*

*By trained, expert radiologists in clinical practice.

57%

Inter-reader agreement

77%

Intra-reader agreement

Visual density assessment is not always consistent.

References:

1. Clinical outcomes in very early breast cancer (≤ 1cm): A national population based analysis. Mahvish Muzaffar, Abdul Rafeh Naqash, Nasreen A. Vohra, Darla K. Liles, and Jan H. Wong Journal of Clinical Oncology 2017 35:15_suppl, e12034-e12034.
2. Gubern-Mérida, A., Kallenberg, M., Platel, B., Mann, R.M., Marfi, R. and Karssemeijer, N. (2014) Volumetric Breast Density Estimation from Full-Field Digital Mammograms: A Validation Study. PLoS ONE; 9: e85952
3. Terry, M.B. et al. 10-year performance of four models of breast cancer risk: a validation study. Lancet Oncol 20, 504-517 (2019).

Disclaimer: The product described is CE-marked and complies with the EU Medical Device Regulation (MDR) 2017/745 and applicable EU standards. It is also FDA-cleared, with the exception of certain features. Please contact your local Lunit representative for more details. Lunit INSIGHT MMG is a Computer-Assisted Detection/Diagnosis (CADe/x) software intended to aid in the detection, localization, and characterization of suspicious breast cancer in mammograms. The device is an adjunctive tool, supporting readings for interpreting physicians. This document is for use by healthcare professionals only. The radiologist should always rely on his or her own clinical and professional opinion when deciding whether to use a certain product to diagnose or treat a patient. Availability of Lunit products may vary by market, depending on local medical and/or regulatory requirements. Please contact your Lunit representative if you have questions about the availability of the Lunit products in your area.

Lunit Inc. owns, uses or enforces the following trademarks or service marks: Lunit, Lunit INSIGHT MMG. Lunit Inc., 4-8 F, 374, Gangnam-daero, Gangnam-gu, Seoul, 06241, Republic of Korea
Document number: mtk7981-4